465 related articles for article (PubMed ID: 25557168)
1. Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
McCarroll JA; Dwarte T; Baigude H; Dang J; Yang L; Erlich RB; Kimpton K; Teo J; Sagnella SM; Akerfeldt MC; Liu J; Phillips PA; Rana TM; Kavallaris M
Oncotarget; 2015 May; 6(14):12020-34. PubMed ID: 25557168
[TBL] [Abstract][Full Text] [Related]
2. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-100 is a potential molecular marker of non-small cell lung cancer and functions as a tumor suppressor by targeting polo-like kinase 1.
Liu J; Lu KH; Liu ZL; Sun M; De W; Wang ZX
BMC Cancer; 2012 Nov; 12():519. PubMed ID: 23151088
[TBL] [Abstract][Full Text] [Related]
4. PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer.
Reda M; Ngamcherdtrakul W; Gu S; Bejan DS; Siriwon N; Gray JW; Yantasee W
Cancer Lett; 2019 Dec; 467():9-18. PubMed ID: 31563561
[TBL] [Abstract][Full Text] [Related]
5. miR-296-5p suppresses cell viability by directly targeting PLK1 in non-small cell lung cancer.
Xu C; Li S; Chen T; Hu H; Ding C; Xu Z; Chen J; Liu Z; Lei Z; Zhang HT; Li C; Zhao J
Oncol Rep; 2016 Jan; 35(1):497-503. PubMed ID: 26549165
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer.
Wang ZX; Xue D; Liu ZL; Lu BB; Bian HB; Pan X; Yin YM
Int J Biochem Cell Biol; 2012 Jan; 44(1):200-10. PubMed ID: 22064247
[TBL] [Abstract][Full Text] [Related]
7. [Study of growth inhibition of gastric cancer cells by sRNA targeting polo like kinase 1 in vitro and vivo].
Lan B; Liu BY; Cheng XH; Qu Y; Zhang XQ; Cai Q; Dai QB; Zhu ZG
Zhonghua Wai Ke Za Zhi; 2006 Jan; 44(1):40-4. PubMed ID: 16620646
[TBL] [Abstract][Full Text] [Related]
8. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
Xu WJ; Zhang S; Yang Y; Zhang N; Wang W; Liu SY; Tian HW; Dai L; Xie Q; Zhao X; Wei YQ; Deng HX
Cancer Biother Radiopharm; 2011 Aug; 26(4):427-36. PubMed ID: 21797676
[TBL] [Abstract][Full Text] [Related]
9. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy.
Yang XZ; Dou S; Sun TM; Mao CQ; Wang HX; Wang J
J Control Release; 2011 Dec; 156(2):203-11. PubMed ID: 21839126
[TBL] [Abstract][Full Text] [Related]
10. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.
Reagan-Shaw S; Ahmad N
FASEB J; 2005 Apr; 19(6):611-3. PubMed ID: 15661849
[TBL] [Abstract][Full Text] [Related]
11. Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells.
Bu Y; Yang Z; Li Q; Song F
Oncology; 2008; 74(3-4):198-206. PubMed ID: 18714168
[TBL] [Abstract][Full Text] [Related]
12. Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells.
Hu K; Law JH; Fotovati A; Dunn SE
Breast Cancer Res; 2012 Feb; 14(1):R22. PubMed ID: 22309939
[TBL] [Abstract][Full Text] [Related]
13. Design of Cationic Multiwalled Carbon Nanotubes as Efficient siRNA Vectors for Lung Cancer Xenograft Eradication.
Guo C; Al-Jamal WT; Toma FM; Bianco A; Prato M; Al-Jamal KT; Kostarelos K
Bioconjug Chem; 2015 Jul; 26(7):1370-9. PubMed ID: 26036843
[TBL] [Abstract][Full Text] [Related]
14. Targeted delivery of polo-like kinase 1 siRNA nanoparticles using an EGFR-PEG bispecific antibody inhibits proliferation of high-risk neuroblastoma.
Logan A; Howard CB; Huda P; Kimpton K; Ma Z; Thurecht KJ; McCarroll JA; Moles E; Kavallaris M
J Control Release; 2024 Mar; 367():806-820. PubMed ID: 38341177
[TBL] [Abstract][Full Text] [Related]
15. In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.
Van den Bossche J; Deben C; De Pauw I; Lambrechts H; Hermans C; Deschoolmeester V; Jacobs J; Specenier P; Pauwels P; Vermorken JB; Peeters M; Lardon F; Wouters A
Mol Oncol; 2019 May; 13(5):1196-1213. PubMed ID: 30859681
[TBL] [Abstract][Full Text] [Related]
16. LSD1 Inhibition Attenuates Tumor Growth by Disrupting PLK1 Mitotic Pathway.
Dalvi PS; Macheleidt IF; Lim SY; Meemboor S; Müller M; Eischeid-Scholz H; Schaefer SC; Buettner R; Klein S; Odenthal M
Mol Cancer Res; 2019 Jun; 17(6):1326-1337. PubMed ID: 30760542
[TBL] [Abstract][Full Text] [Related]
17. [Influence of silencing Polo-like kinase 1 on migration and invasion of colorectal cancer cells].
Han DP; Cui JT; Lu AG; Chen XH; Feng B; Zong YP; Qu S; Cao QF; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2011 Jan; 14(1):61-4. PubMed ID: 21271384
[TBL] [Abstract][Full Text] [Related]
18. Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
Ding Y; Huang D; Zhang Z; Smith J; Petillo D; Looyenga BD; Feenstra K; Mackeigan JP; Furge KA; Teh BT
Cancer Res; 2011 Aug; 71(15):5225-34. PubMed ID: 21642374
[TBL] [Abstract][Full Text] [Related]
19. miR-593-5p inhibit cell proliferation by targeting PLK1 in non small cell lung cancer cells.
Yan L; Zhang Y; Li K; Wang M; Li J; Qi Z; Wu J; Wang Z; Ling L; Liu H; Wu Y; Lu X; Xu L; Zhu Y; Zhang Y
Pathol Res Pract; 2020 Feb; 216(2):152786. PubMed ID: 31864714
[TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of PLK1-siRNA by ScFv suppresses Her2+ breast cancer growth and metastasis.
Yao YD; Sun TM; Huang SY; Dou S; Lin L; Chen JN; Ruan JB; Mao CQ; Yu FY; Zeng MS; Zang JY; Liu Q; Su FX; Zhang P; Lieberman J; Wang J; Song E
Sci Transl Med; 2012 Apr; 4(130):130ra48. PubMed ID: 22517885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
